A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough (2024)
Fonte: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. Unidade: FM
Assuntos: ANTIMETABÓLITOS, COLESTEROL, LIPOPROTEÍNAS LDL, DISLIPIDEMIAS
ABNT
SANTOS FILHO, Raul Dias dos e NASIR, Khurram e SHAPIRO, Michael David. A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. NEW YORK: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://observatorio.fm.usp.br/handle/OPI/81896. Acesso em: 23 nov. 2025. , 2024APA
Santos Filho, R. D. dos, Nasir, K., & Shapiro, M. D. (2024). A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. NEW YORK: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jacc.2024.09.019NLM
Santos Filho RD dos, Nasir K, Shapiro MD. A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough [Internet]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024 ; 84( 20): 2048-2050.[citado 2025 nov. 23 ] Available from: https://observatorio.fm.usp.br/handle/OPI/81896Vancouver
Santos Filho RD dos, Nasir K, Shapiro MD. A Step Forward for Long-Acting PCSK9 Inhibition Improvements Without a Breakthrough [Internet]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2024 ; 84( 20): 2048-2050.[citado 2025 nov. 23 ] Available from: https://observatorio.fm.usp.br/handle/OPI/81896
